|Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.|
|PMID: 15269705 Owner: NLM Status: MEDLINE|
|Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism. We assessed the efficacy of moxonidine in a postmarketing surveillance study (CAMUS) conducted in 772 practices in Germany, documenting 4005 patients with hypertension, who were overweight and/or suffered from metabolic syndrome. Patients were treated with moxonidine (Cynt) for the first time following the baseline visit for 8 weeks. Mean blood pressure decreased from 168/97 to 141/83 mmHg for all patients and from 168/96 to 141/83 mmHg for patients with metabolic syndrome. Blood pressure reduction was particularly pronounced in patients with severe hypertension at baseline. The response rate (DBP< or =90 mmHg or reduction > or =10 mmHg) of antihypertensive treatment with moxonidine was 94.0% for all patients and 93.8% for patients with metabolic syndrome. The recommended targets for antihypertensive treatment of the German Diabetes Society/German Hypertension Society were reached by 30.5% of nondiabetics (goal: <140/90 mmHg) and by 3.6% of diabetics (goal: <130/80 mmHg) observed. After 8 weeks of treatment, patients achieved a mean weight loss of 1.4 kg, which was particularly pronounced in obese patients. The rate of patients receiving antihypertensive combination therapy was 81.1% for those with metabolic syndrome, and 63.3% for all other patients. Patients with metabolic syndrome were preferentially treated with ACE inhibitors and diuretics. We conclude that moxonidine effectively reduces blood pressure in patients with metabolic syndrome while simultaneously reducing body weight in obese patients.|
|A M Sharma; T Wagner; P Marsalek|
Related Documents :
|594795 - Failure of single-session dietary counseling to reduce salt intake in hypertensive pati...
7654725 - Preliminary experience with inhaled nitric oxide for acute pulmonary hypertension after...
6348805 - Reduced urinary excretion of prostaglandin e in essential hypertension.
21422675 - Gastric mucosal damage evaluated by transnasal endoscopy and qol assessments in ischemi...
433875 - Endocrine abnormalities in thalassemia major.
22996745 - Altered brain functional connectivity in patients with cirrhosis and minimal hepatic en...
|Type: Journal Article|
|Title: Journal of human hypertension Volume: 18 ISSN: 0950-9240 ISO Abbreviation: J Hum Hypertens Publication Date: 2004 Sep|
|Created Date: 2004-08-23 Completed Date: 2006-07-07 Revised Date: 2006-11-15|
Medline Journal Info:
|Nlm Unique ID: 8811625 Medline TA: J Hum Hypertens Country: England|
|Languages: eng Pagination: 669-75 Citation Subset: IM|
|McMaster University, Hamilton, ON, Canada.|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Antihypertensive Agents / adverse effects, therapeutic use*
Biological Markers / blood
Blood Glucose / metabolism
Blood Pressure / drug effects
Body Mass Index
Cholesterol, HDL / blood
Drug Therapy, Combination
Germany / epidemiology
Heart Rate / drug effects
Hypertension / blood, drug therapy*, epidemiology
Imidazoles / adverse effects, therapeutic use*
Metabolic Syndrome X / blood, drug therapy*, epidemiology
Obesity / blood, drug therapy*, epidemiology
Product Surveillance, Postmarketing
Severity of Illness Index
Triglycerides / blood
|0/Antihypertensive Agents; 0/Biological Markers; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Imidazoles; 0/Triglycerides; 75438-57-2/moxonidine|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia...
Next Document: Baseline Na-Li countertransport and risk of hypertension in children: a 10-year prospective study in...